Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Dan Udrea

Child & Adolescent Psychiatry Wexford, PA Medical Doctor

NPI 1104072800 CMS profile 764963

6500 Brooktree Rd, Suite 208, Wexford, PA 15090

Open in the dashboard

General payments

$51,081

331 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dan Udrea of Wexford, PA is reported in the CMS Open Payments database as having received $51,081 across 331 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,671 135
2024 General $1,128 55
2023 General $5,272 68
2022 General $468 37
2021 General $508 33
2020 General $34 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dan Udrea
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Dan Udrea were reported at $43,671. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Dan Udrea Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $34 $81 $28–$226 $114
2021 $508 $115 $31–$326 $132
2022 $468 $124 $40–$382 $149
2023 $5,272 $130 $45–$420 $160
2024 $1,128 $141 $42–$490 $164
2025 $43,671 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Supernus Pharmaceuticals, Inc. $43,341 112 payments
  2. Corium, Inc. $4,912 54 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $618 57 payments
  4. Ironshore Pharmaceuticals Inc. $599 32 payments
  5. Tris Pharma Inc $417 12 payments
  6. Janssen Pharmaceuticals, Inc $400 16 payments
  7. Collegium Pharmaceutical, Inc. $211 13 payments
  8. AbbVie, Inc. $131 7 payments
  9. Neos Therapeutics, LP $107 6 payments
  10. ITI, Inc. $98 6 payments
  11. Other $247 16 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Honoraria $38,250 15 payments
  2. Food and Beverage $5,489 289 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,360 2 payments
  4. Travel and Lodging $3,234 20 payments
  5. Consulting Fee $720 2 payments
  6. Education $28 3 payments
Products named General payments · program years 2020–2025
  1. Qelbree Viloxazine Hydrochloride $43,066 87 payments
  2. Azstarys $4,912 54 payments
  3. JORNAY PM Central Nervous System Stimulant $443 21 payments
  4. TRINTELLIX $421 28 payments
  5. SPRAVATO $400 16 payments
  6. QELBREE Psychology $274 25 payments
  7. Quillivant $235 1 payment
  8. Jornay PM Adhd $211 13 payments
  9. VYVANSE $175 27 payments
  10. JORNAY PM Central Nervous Stimulant ADHD $157 11 payments
  11. Other $804 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

331 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record